RXST · RxSight, Inc.
$4.86
+0.09 (+1.89%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$193.82M
Shares
41.59M
Volume · Sep 30
705.67K
Avg daily vol (3M)
989.85K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.77
Open$4.67
Day$4.62–4.78
52W close$4.59–13.09
Avg vol 30d836K
Short int4.0M · 9.6% float · 5.5d
Short vol49%
Last earningsJul 7, 2026
DataJul 2021–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Oct 6, 2026
Est · unconfirmed
· in 1 wks
filed Aug 5, 2026
call held May 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$127.58M
Trailing 12 months
Net income (TTM)
−$46.95M
Trailing 12 months
Revenue growth YoY
+0.3%
Year over year
Operating margin
-43.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-14.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.8%
Year over year · more shares
Price change (1Y)
-49.1%
Trailing year
Short interest
9.6%
Latest settlement · 5.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.38
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−33%
below
Price vs 50-day avg
−21%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−35%
trailing
6-month return
−34%
trailing
YTD return
−54%
this year
Relative strength
−48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$118.0K over 90 days · 100% sells
Short interest
Rising
9.56% of float · ▲ +2.6% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
151 holders — mid 3-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
Gross margin
77%
expanding
EPS growth
−34%
Y/Y
Free cash flow
$-19.3M
Balance sheet
$9.7M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 5, 2026
2026 full year revenue
· 2026 full year
Initiated
$140M – $160M
prior FY $134.48M
midpoint +11.5% Y/Y
Full-year gross margin
· 2026 full year
Initiated
73% – 75%
Operating expenses
· 2026 full year
Initiated
$150M – $160M
Guided vs delivered
· last 2 settled
Revenue
2024 full-year
guided $139M – $140M
$139.93M
In line
Revenue
full-year 2023
guided $85M – $87M
$89.08M
Beat +3.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−33%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$118.0K over 90 days · 100% sells
Short interest
Rising
9.56% of float · ▲ +2.6% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
151 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $5 · 2%
Range high $13
vs 200-day avg -33%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RXST
this stock
RxSight, Inc.
|
$193.82M | -54.2% | -3.9% | — | 9.6% |
|
ABT
Abbott Laboratories
|
$174.90B | -19.4% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -9.3% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -20.7% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.0% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RXST | -3.3% | -34.9% | -34.5% | -34.9% | -54.2% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -2.1% | -34.6% | -47.5% | -34.6% | -66.3% |